The recent surge in investments into boutique pharmaceutical companies, particularly those focusing on novel therapies and difficult drug development programs, has fueled what some are calling "High Investor Pharma." While the potential for blockbuster treatments and substantial returns is undeniable, the connected risks are also notable. Many of t